ISSN: 1230-2813
Advances in Psychiatry and Neurology/Postępy Psychiatrii i Neurologii
Current issue Archive Manuscripts accepted About the journal Scientific board Abstracting and indexing Subscription Contact Instructions for authors Ethical standards and procedures
SCImago Journal & Country Rank
4/2020
vol. 29
 
Share:
Share:
more
 
 
abstract:
Original paper

Can irisin become a biomarker of physical activity, or another metabolic risk assessment parameter, in psychiatric care patients?

Wojciech Łężak
1
,
Łukasz Mokros
2
,
Jakub M. Kaźmierski
3
,
Dominik Strzelecki
4
,
Hanna Jerczyńska
5
,
Edward Kowalczyk
1
,
Tadeusz Pietras
2, 6

1.
Department of Pharmacology and Toxicology, Medical University of Lodz, Poland
2.
Department of Clinical Pharmacology of the 1st Chair of Internal Diseases, Medical University of Lodz, Poland
3.
Department of Old Age Psychiatry and Psychotic Disorders, Medical University of Lodz, Poland
4.
Department of Affective and Psychotic Disorders, Medical University of Lodz, Poland
5.
Central Scientific Laboratory (CoreLab), Medical University of Lodz, Poland
6.
Department of Neuroses, Personality Disorders and Eating Disorders, Institute of Psychiatry and Neurology, Warsaw, Poland
Adv Psychiatry Neurol 2020; 29 (4): 205-214
Online publish date: 2021/01/30
View full text
Get citation
ENW
EndNote
BIB
JabRef, Mendeley
RIS
Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
 
Introduction
Physical activity (PA) is considered to be a major preventive factor in psychopharmacotherapy-induced metabolic adverse effects, such as metabolic syndrome induction. The recent discovery of irisin might bring a potential tool with which to supervise patient compliance or create an additional metabolic risk assessment parameter

Material and methods
The sample consisted of 66 in- and out-patients of a Polish hospital. Irisin serum concentrations were measured using commercially available ELISA kits. Sociodemographic and clinical data were obtained from medical records. PA sufficiency was assessed with the use of the International Physical Activity Questionnaire. t-Student, c2 , Fisher’s exact test, Pearson correlation and ANCOVA were used for statistical analysis. The significance level was set at α = 0.05.

Results
The difference in irisin concentrations between patients with sufficient and insufficient PA was not statistically significant. Patients given second generation antipsychotic drugs exhibited lower PA and irisin concentrations than patients on antidepressant drugs or first-generation antipsychotic drugs. Additionally, irisin concentrations were lower in patients with central obesity compared to patients without it.

Conclusions
Irisin does not appear to be a valid, objective tool for the evaluation of patients. However, significant associations between irisin concentrations, psychopharmacotherapy and metabolic parameters were found.

keywords:

metabolic syndrome, antipsychotics, antidepressants, psychopharmacotherapy, irisin

Quick links
© 2021 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.
PayU - płatności internetowe